Day One Biopharmaceuticals I (DAWN) Technical Analysis
$6.75▲7.06%
Market is closed - opens 7 PM, 09 May 2025
Insights
- Day One Biopharmaceuticals I is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Day One Biopharmaceuticals I stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Day One Biopharmaceuticals I stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 40.21 | Neutral |
Stochastic | 26.5, 17.78 | Neutral |
Ultimate Oscillator | 34.83 | Neutral |
Stochastic Relative Strength Index | 20.74, 37.61 | Neutral |
Moving Average Convergence Divergence | -0.27, -0.24 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.4 | Buy |
20 | 7.29 | Sell |
50 | 7.86 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.18 | Sell |
20 | 7.37 | Sell |
50 | 8.21 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.25 | Sell |
20 | 7.2 | Sell |
50 | 7.88 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.95 | Sell |
20 | 7.0 | Buy |
50 | 6.68 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 6.77 | Sell |
20 | 7.15 | Buy |
50 | 6.58 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 8.39 |
Resistance L2 | 7.95 |
Resistance L1 | 7.13 |
Pivot Point | 6.69 |
Support L1 | 5.87 |
Support L2 | 5.43 |
Support L3 | 4.61 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.